Mission Statement

The American College of Spine Surgery was organized in 1999 with Charles D. Ray serving as the founding president.
The College was created with the following objectives:

  • to promote suitable and appropriate education and training in the field of spine surgery;
  • to sponsor suitable and appropriate educational programs in the field of spine surgery; and
  • to accredit suitable and appropriate residency and fellowship training programs in the field of spine surgery.

Corey Wallach, M.D.
ACSS Spine Surgeons Aid Poor in Mexico
Dr. Dennis Cramer and Dr. Haider share their skills to help in Guadalajara, Mexico.


Meeting Co-Chairs

  Adam Shimer, M.D.  Paul Gause, M.D.  

Latest News

Melanie Morel-Ferris, CPA, will become Cambridge, Mass.-based InVivo Therapeutics' interim CFO, effective Jan. 2, 2017.

FirstCare Health Plans in Austin, Texas, selected Buffalo, N.Y.-based Palladian Health and Seattle-based MCG Health for the partnership's spine care management program.

Shoulder replacements are increasing in prevalence nationally, according to Loyola Medicine.

Cleveland Clinic addressed physician burnout by offering a training session emphasizing relationship-centered communication, according to AMA Wire.

The global minimally invasive spine surgery market will likely grow at a compound annual growth rate of 7.57 percent between 2016 and 2020, based on a ResearchMoz report, according to medGadget.

Here are eight things for spinal surgeons to know for Dec. 8, 2016.

A new study published in Spine compares posterolateral fusion with interbody fusion for patients with degenerative spondylolisthesis.

Chesterfield, U.K.-based Mallinckrodt Pharmaceuticals reported results from a study of the company's OFIRMEV (acetaminophen) injections. OFIRMEV is the only intravenous formulation of acetaminophen that is FDA approved and marketed in the United States. The study compared the use of oral acetaminophen versus use of IV acetaminophen as part of an analgesic management program for post-spine surgical pain.

New York City-based Mount Sinai Health System unveiled the Medical Modeling Core, which leverages the collaboration between clinical and scientific experts.

An infant with spinal muscular atrophy type 1 became the first baby to receive an experimental drug, nusinersen, to treat her condition in 2013, according to Medical Xpress.